Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar

NEW YORK, October 16, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Incyte Corporation (NASDAQ: INCY), and Nektar Therapeutics (NASDAQ: NKTR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Questcor Pharmaceuticals, Inc. Research Report  

On October 10, 2013, Questcor Pharmaceuticals, Inc.'s (Questcor) Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis), payable on or about October 30, 2013 to shareholders of record at the close of business on October 22, 2013. Questcor reported that the recently announced dividend reflects an increase of $0.05 or 20% QoQ and a 50% YoY. "Our second dividend increase this year reflects our strong financial performance to date, driven by increasing usage of Acthar among physicians to treat patients with serious, difficult to treat medical conditions," said Don M. Bailey, President and CEO of Questcor. "Our business is generating a growing amount of cash flow, as evidenced by Questcor's $278 million in cash and investments at October 4, 2013. Our cash position includes $75 million in restricted cash, unchanged from the second quarter 2013. We remain committed to using our strong cash flow to invest in our business, including significant investments in R&D, while returning cash to shareholders. To date we have maintained a payout ratio-dividends paid per share divided by earnings per share-of approximately 20%." The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/a415_QCOR]

--

Regeneron Pharmaceuticals, Inc. Research Report

On October 10, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that it will release its Q3 2013 financial and operating results before the US markets open on Tuesday, November 5, 2013. Regeneron reported that it will also host a conference call and webcast on the same day at 8:30 a.m. ET. According to the Company, interested parties may access the call through the Events and Presentations section of its website, wherein a replay of the call and its webcast will be available for 30 days. The Full Research Report on Regeneron Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/8ea7_REGN]

--

NPS Pharmaceuticals, Inc. Research Report

On October 7, 2013, NPS Pharmaceuticals, Inc. (NPS) announced that it presented findings from REPLACE, its pivotal Phase 3 study of Natpara (recombinant human parathyroid hormone 1-84, rhPTH (1-84)), suggesting that the investigational therapy has a beneficial effect on bone health in patients with hypoparathyroidism. According to NPS, investigators also reported findings from the PARADOX burden of illness survey suggesting that patients with hypoparathyroidism have a substantial burden of illness in the skeleton and joints and experience bone-related symptoms and comorbidities despite receiving standard care, such as calcium and active vitamin D. The Company stated that the findings from REPLACE and PARADOX were presented in respective poster sessions at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Baltimore, Maryland. The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP]

--

Incyte Corporation Research Report

On October 10, 2013, Incyte Corporation (Incyte) announced that it will release its Q3 2013 results on Thursday, October 31, 2013 at 7:00 a.m. ET, which will be followed by a conference call at 8:30 a.m. ET on the same day. Incyte reported that interested parties may access a live webcast of the conference call through its Investor Relations, Events, and Webcast sections of the website. The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/076e_INCY]

--

Nektar Therapeutics Research Report

On October 8, 2013, Nektar Therapeutics (Nektar) presented an overview of its proprietary drug candidate pipeline during the Company's R&D Day for investors and analysts in New York City. According to Nektar, it presented data from two Phase 2 studies of NKTR-181, the Company's novel mu-opioid analgesic molecule, followed by new topline clinical data from an ongoing investigator-sponsored Phase 2 study of Nektar's proprietary cancer drug candidate, NKTR-102, in patients with Avastin-resistant high-grade glioma, as well as new receptor-based research for NKTR-192, the Company's novel analgesic molecule for acute pain that is currently in Phase 1 development. Howard W. Robin, President and CEO of Nektar, said, "Nektar has one of the most exciting and robust pipelines in the biotech industry. In addition to our four partnered programs, which are in or have completed Phase 3 studies, we have a deep proprietary pipeline of novel therapeutic candidates." The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/3421_NKTR]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner